A Study for Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.

Also called NCT01027871

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 289 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01027871
Other papers using this trial's data
  • A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes Diabetes care, 2012-11 DOI, PubMed 22787177, PMC3476888 In the PMC Open Access subset under CC BY-NC-ND.
  • Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine Diabetes care, 2014 DOI, PubMed 24198302

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Hungary, Poland, Puerto Rico, Romania, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01027871. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2018-06-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study for Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2605541
Intervention (Drug)
insulin glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01027871
Content hash
c6945902b8527cfb168652d5a6b9b60f791fd081b81c775945aff5073f0dd994